GlassScriptPhysician profile
Naeemuddin Jatoi
NPI 1922070333
$9,714.30
in general payments reported to CMS, 2019-2025
38 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $916 · 2021: $1,396 · 2022: $1,520 · 2023: $1,752 · 2024: $1,863 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,342 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,342.12 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,131.54 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,018.59 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $976.68 | 2020-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $906.51 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $673.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $597.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $501.15 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $421.53 | 2019-2025 | |
| Astellas Pharma US INC | $384.43 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.95 | 2019-2025 | Jardiance, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $306.45 | 2020-2023 | Xarelto |
| Mylan Specialty L.P. | $293.69 | 2019-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $290.42 | 2019-2024 | Austedo Xr, Austedo |
| Abbott Laboratories | $278.56 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $272.53 | 2019-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeemuddin Jatoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.